WHO warns of growing resistance to GSK HIV drug

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-03-06 07:00 GMT | Update On 2024-03-20 10:50 GMT

The World Health Organization (WHO) has said resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey data received from a few countries.Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV...

Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.

HIV medicines reduce the amount of the virus in the body to a very low level and helps prevent illness.

"The resistance analysis focuses on subgroups whose virus was not suppressed and the data does not indicate that resistance was prevalent in the overall population", a GSK spokesperson said on Tuesday.

The global health agency did not disclose the number of countries from where the data was reported, but said only a few countries have reported survey data to WHO, to date.

Only Haiti reported survey data to the WHO for HIV drug resistance among infants who have not received the therapy or infants starting it.

The WHO said there have been cases of resistance to a class of HIV drugs known as integrase-strand transfer inhibitors in patients who took the injectible version of an HIV preventive drug called cabotegravir or CAB-LA.

Cabotegravir, also made by GSK, is sold under the brand name Apretude.

The WHO recommended that countries routinely implement standardized surveillance of resistance to HIV drugs, which could help understand the patterns of resistance among people not achieving a suppressed viral load.

"We agree with the WHO that there is a need for further surveillance," GSK said.

The agency has been recommending the use of dolutegravir as the preferred first- and second-line HIV treatment for all population groups since 2018.

It has recommended use of long-acting injectable cabotegravir as an additional prevention for those at substantial risk of HIV infection since 2022.

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/who-says-resistance-gsks-hiv-drug-is-growing-2024-03-05/

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

WHO warns of growing resistance to GSK HIV drug

Similar News